A Phase II trial of the anti-CD40 drug, which Horizon Therapeutics acquired in early 2021, met its primary endpoint in Sjögren’s, showing potential utility across multiple autoimmune indications.
Horizon Therapeutics plc’s acquisition of Viela Bio in early 2021 is showing signs of paying off as one of the key assets in that acquisition, dazodalibep, produced positive results in a Phase II study in Sjögren’s syndrome (SS).
The company announced 12 September that the Phase II trial, in SS patients with moderate-to-high systemic disease activity, met its primary endpoint of at least a five-point reduction in the...
Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.
But the French major is still keen on early-stage M&A.
Buy boosts the French major's immunology pipeline.
